Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem-Resistant Enterobacterales
- Conditions
- Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated intra-abdominal infection (cIAI)MedDRA version: 21.0Level: LLTClassification code 10080628Term: Complicated urinary tract infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10079985Term: Uncomplicated pyelonephritisSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: LLTClassification code 10081414Term: Ventilator associated bacterial pneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10079983Term: Complicated intra-abdominal infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: LLTClassification code 10081416Term: Hospital acquired bacterial pneumoniaSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Registration Number
- EUCTR2021-001396-16-SK
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 151
Patients who meet all of the following criteria will be eligible to participate in the study:
1. Male or female patients = 18 years of age (or age of legal consent, whichever is older) at the time of obtaining informed consent and who can be hospitalized throughout the Treatment Period;
2. Weight = 140 kg;
3. The following criteria must be satisfied:
a. For known CRE infection, meets either of the following (i or ii):
i. Has a known CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence from CRE culture, susceptibility testing, and possible carbapenemase phenotypic testing (or possible molecular testing) within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; AND
Has received no more than 24 hours of an antimicrobial agent to which the known CRE is known to be susceptible within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug;
OR
ii. Has a known CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence from CRE culture, susceptibility testing, and possible carbapenemase phenotypic testing (or possible molecular testing ) within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug; AND
Has documented clinical evidence of failure (ie, clinical deterioration or failure to improve) after at least 48 hours of treatment with an antimicrobial agent to which the known CRE is known to be susceptible within 72 hours (or 96 hours for cIAI)
prior to the first dose of study drug;
b. For suspected CRE infection, meets the following (i or ii):
i. Has a suspected CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence which may be determined within 90 days prior to the first dose of study drug through rapid diagnostic tests, active surveillance cultures, other documentation of CRE colonization, or prior infection due to a CRE pathogen; AND
Has received no more than 24 hours of empiric antimicrobial therapy for Gram-negative organisms within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug;
OR
ii. Has a suspected CRE infection, alone or as a single isolate of a polymicrobial infection, based on evidence which may be determined within 90 days prior to the first dose of study drug through rapid diagnostic tests, active surveillance cultures, other documentation of CRE colonization, or prior infection due to a CRE pathogen; AND
Has documented clinical evidence of failure (ie, clinical deterioration or failure to improve) after at least 48 hours of treatment with empiric antimicrobial therapy for Gram-negative organisms within 72 hours (or 96 hours for cIAI) prior to the first dose of study drug;
Note: CRE is defined as Enterobacterales by susceptibility data of minimum inhibitory concentration (MIC) = 2 µg/mL to imipenem or meropenem OR imipenem or meropenem disk diffusion (zone diameter < 22 mm). If MIC or disk diffusion data are not available in the local laboratory or before the availability of MIC or disk diffusion results, each site can use other susceptibility testing and criteria in the institution as the initial evidence of CRE for enrollment. In any case, pathogen identification and susceptibility testing performed at the central laboratory will be used to determine CRE in the final study analysis.
Note: Complete list of inclusion criteria is in the protocol.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18
Patients who meet any of the following criteria will be excluded from participation in the study:
1. Has a history of serious allergy, hypersensitivity (eg, anaphylaxis), or any serious allergic
reaction to carbapenems, cephems, penicillins, other B-lactam antibiotics, or any B-lactamase inhibitors (eg, tazobactam, sulbactam, or clavulanic acid) or to any of the excipients;
2. Has known or suspected single or concurrent infection with Acinetobacter spp., metallo-ßlactamase (MBL) producing Pseudomonas aeruginosa, or other organisms that are not adequately covered by the study drug (eg, concurrent viral, mycobacterial, or fungal infection) and need to be managed with other anti-infectives;
Note: Patients with qualifying Gram-negative pathogen coinfected (or suspected to be coinfected) with a Gram-positive pathogen may be administered narrow spectrum, open-label glycopeptide (eg, vancomycin), oxazolidinone (eg, linezolid), or daptomycin concomitantly with the study drug at the discretion of the Investigator. Patients with cIAI may receive metronidazole in addition to cefepime/nacubactam, aztreonam/nacubactam, or as part of best available therapy (BAT) if anaerobic coverage is deemed necessary. When these drugs are used as a concomitant drug, the investigator should confirm the patient does not have hypersensitivity to that drug or excipient before use. Note: Patients in whom a carbapenem-resistant Pseudomonas aeruginosa is identified may be continued on the study drug only if the patient was (1) enrolled in this study as a suspected CRE, (2) the causative organism is found to be P. aeruginosa after randomization, (3) does not meet exclusion or discontinuation criteria, and (4) the patient is clinically improving on study drug.
3. Has only a Gram-positive organism pathogen isolated from study-qualifying culture;
Note: Complete list of exclusion criteria is in the protocol.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method